-
Loading metrics
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
- Javier Morales-Ramirez,
- Johannes R. Bogner,
- Jean-Michel Molina,
- Johan Lombaard,
- Ira B. Dicker,
- David A. Stock,
- Michelle DeGrosky,
- Margaret Gartland,
- Teodora Pene Dumitrescu,
- Sherene Min,
- Cyril Llamoso,
- Samit R. Joshi,
-
Max Lataillade
Roles Formal analysis
* E-mail: max.x.lataillade@viivhealthcare.com
Affiliation ViiV Healthcare, Branford, Connecticut, United States of America
⨯
http://orcid.org/0000-0001-6103-8967
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
- Javier Morales-Ramirez,
- Johannes R. Bogner,
- Jean-Michel Molina,
- Johan Lombaard,
- Ira B. Dicker,
- David A. Stock,
- Michelle DeGrosky,
- Margaret Gartland,
- Teodora Pene Dumitrescu,
- Sherene Min
x
- Published: October 23, 2018
- https://doi.org/10.1371/journal.pone.0205368